Arlene B Chapman

List of Publications by Year
in descending order

69 papers	3,680 citations	136950 32 h-index	133252 59 g-index
71 all docs	71 docs citations	71 times ranked	3493 citing authors

#	Article	IF	Citations
1	Imaging Classification of Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2015, 26, 160-172.	6.1	439
2	Kidney Volume and Functional Outcomes in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 479-486.	4.5	305
3	Hypertension in Autosomal Dominant Polycystic Kidney Disease. Advances in Chronic Kidney Disease, 2010, 17, 153-163.	1.4	141
4	The HALT Polycystic Kidney Disease Trials. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 102-109.	4.5	125
5	Pharmacogenomics of antihypertensive drugs: Rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. American Heart Journal, 2009, 157, 442-449.	2.7	119
6	Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney International, 2002, 61, 1047-1055.	5.2	108
7	Genomic Association Analysis Suggests Chromosome 12 Locus Influencing Antihypertensive Response to Thiazide Diuretic. Hypertension, 2008, 52, 359-365.	2.7	106
8	Approaches to Testing New Treatments in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1197-1204.	4.5	103
9	Genomic Association Analysis of Common Variants Influencing Antihypertensive Response to Hydrochlorothiazide. Hypertension, 2013, 62, 391-397.	2.7	96
10	Health-Related Quality of Life in Patients With Autosomal DominantÂPolycystic Kidney Disease and CKD Stages 1-4: AÂCross-sectional Study. American Journal of Kidney Diseases, 2014, 63, 214-226.	1.9	93
11	Liver Involvement in Early Autosomal-Dominant Polycystic Kidney Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 155-164.e6.	4.4	90
12	Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney International, 2018, 93, 691-699.	5.2	76
13	Autosomal Dominant Polycystic Kidney Disease: Time for a Change?. Journal of the American Society of Nephrology: JASN, 2007, 18, 1399-1407.	6.1	75
14	Pharmacogenomics of Hypertension: A Genomeâ€Wide, Placeboâ€Controlled Crossâ€Over Study, Using Four Classes of Antihypertensive Drugs. Journal of the American Heart Association, 2015, 4, e001521.	3.7	74
15	G protein receptor kinase 4 polymorphisms. Hypertension, 2012, 60, 957-964.	2.7	65
16	Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. Journal of Hypertension, 2013, 31, 698-704.	0.5	63
17	Mechanisms and management of hypertension in autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2014, 29, 2194-2201.	0.7	60
18	Genomic Association Analysis Identifies Multiple Loci Influencing Antihypertensive Response to an Angiotensin II Receptor Blocker. Hypertension, 2012, 59, 1204-1211.	2.7	59

#	Article	IF	Citations
19	Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease. Kidney International, 2019, 95, 1253-1261.	5.2	59
20	Hypertension Susceptibility Loci and Blood Pressure Response to Antihypertensives. Circulation: Cardiovascular Genetics, 2012, 5, 686-691.	5.1	55
21	Image texture features predict renal function decline in patients with autosomal dominantÂpolycystic kidney disease. Kidney International, 2017, 92, 1206-1216.	5.2	54
22	Predictors of Blood Pressure Response to the Angiotensin Receptor Blocker Candesartan in Essential Hypertension. American Journal of Hypertension, 2008, 21, 61-66.	2.0	52
23	Imaging Approaches to Patients With Polycystic Kidney Disease. Seminars in Nephrology, 2011, 31, 237-244.	1.6	50
24	Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial. Nephrology Dialysis Transplantation, 2016, 31, 1887-1894.	0.7	46
25	Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease. Kidney International, 2020, 97, 370-382.	5.2	44
26	Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to Î²-Blockers in Hypertensive African Americans. Hypertension, 2016, 67, 556-563.	2.7	41
27	Cystic Disease in Women: Clinical Characteristics and Medical Management. Advances in Chronic Kidney Disease, 2003, 10, 24-30.	2.1	39
28	PTPRD gene associated with blood pressure response to atenolol and resistant hypertension. Journal of Hypertension, 2015, 33, 2278-2285.	0.5	38
29	Tolvaptan and Kidney Pain in Patients With Autosomal DominantÂPolycystic Kidney Disease: Secondary Analysis FromÂa Randomized Controlled Trial. American Journal of Kidney Diseases, 2017, 69, 210-219.	1.9	37
30	Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4. Kidney International Reports, 2017, 2, 1132-1140.	0.8	35
31	Automated Segmentation of Kidneys from MR Images in Patients with Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 576-584.	4.5	34
32	Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide. Hypertension, 2017, 69, 51-59.	2.7	34
33	Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial. Journal of Clinical Pharmacology, 2017, 57, 906-917.	2.0	30
34	A Novel Simple Method for Determining CYP2D6 Gene Copy Number and Identifying Allele(s) with Duplication/Multiplication. PLoS ONE, 2015, 10, e0113808.	2.5	30
35	Demographic, Environmental, and Genetic Predictors of Metabolic Side Effects of Hydrochlorothiazide Treatment in Hypertensive Subjects. American Journal of Hypertension, 2005, 18, 1077-1083.	2.0	29
36	TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives. Journal of Hypertension, 2015, 33, 1301-1309.	0.5	29

#	Article	IF	Citations
37	Identification of Distinct Glycoforms of IgA1 in Plasma from Patients with Immunoglobulin A (IgA) Nephropathy and Healthy Individuals. Molecular and Cellular Proteomics, 2014, 13, 3097-3113.	3.8	28
38	Nurturing Passion in a Time of Academic Climate Change. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1878-1883.	4.5	24
39	Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC). American Journal of Kidney Diseases, 2015, 66, 583-590.	1.9	21
40	A Genetic Response Score for Hydrochlorothiazide Use. Hypertension, 2016, 68, 621-629.	2.7	21
41	Lack of agreement between office and ambulatory blood pressure responses to hydrochlorothiazide. American Journal of Hypertension, 2005, 18, 398-402.	2.0	20
42	Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics. Journal of the American Heart Association, 2018, 7, .	3.7	19
43	Promoters of Human Cosmc and T-synthase Genes Are Similar in Structure, Yet Different in Epigenetic Regulation. Journal of Biological Chemistry, 2015, 290, 19018-19033.	3.4	18
44	The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations. Kidney International Reports, 2020, 5, 801-812.	0.8	16
45	Pharmacogenomic studies of hypertension: paving the way for personalized antihypertensive treatment. Expert Review of Precision Medicine and Drug Development, 2018, 3, 33-47.	0.7	13
46	Genome-Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated With Thiazide Diuretics Blood Pressure Response. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	11
47	Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension. Journal of Clinical Hypertension, 2017, 19, 1301-1308.	2.0	11
48	Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach. Metabolomics, 2016, 12, 1.	3.0	10
49	Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy. Pharmacogenetics and Genomics, 2019, 29, 18-22.	1.5	10
50	A Physiologic Approach to the Pharmacogenomics of Hypertension. Advances in Chronic Kidney Disease, 2016, 23, 91-105.	1.4	9
51	Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension. American Journal of Hypertension, 2019, 32, 668-675.	2.0	9
52	Pharmacogenomics of Hypertension in CKD: The CKD-PGX Study. Kidney360, 2022, 3, 307-316.	2.1	9
53	The fetal environment: a critical phase that determines future renal outcomes in autosomal dominant polycystic kidney disease. Kidney International, 2012, 81, 814-815.	5.2	8
54	Sorting nexin 1 loss results in increased oxidative stress and hypertension. FASEB Journal, 2020, 34, 7941-7957.	0.5	8

#	Article	IF	Citations
55	Reproducibility of Blood Pressure Response to Hydrochlorothiazide. Journal of Clinical Hypertension, 2002, 4, 408-412.	2.0	7
56	Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease. Kidney International Reports, 2018, 3, 619-624.	0.8	7
57	Protein kinase CÎ± deletion causes hypotension and decreased vascular contractility. Journal of Hypertension, 2018, 36, 510-519.	0.5	7
58	Metabolomics Signature of Plasma Renin Activity and Linkage with Blood Pressure Response to Beta Blockers and Thiazide Diuretics in Hypertensive European American Patients. Metabolites, 2021, 11, 645.	2.9	7
59	Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies. BMC Medical Genomics, 2018, 11, 55.	1.5	6
60	A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD. Kidney International Reports, 2020, 5, 790-800.	0.8	6
61	Night Blood Pressure Responses to Atenolol and Hydrochlorothiazide in Black and White Patients With Essential Hypertension. American Journal of Hypertension, 2014, 27, 546-554.	2.0	5
62	Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics. Scientific Reports, 2017, 7, 16068.	3.3	5
63	â€˜A sword of Damoclesâ€™: patient and caregiver beliefs, attitudes and perspectives on presymptomatic testing for autosomal dominant polycystic kidney disease: a focus group study. BMJ Open, 2020, 10, e038005.	1.9	5
64	Improving clinical trial design for inquiries into the mechanisms of cyst growth in ADPKD. Kidney International, 2009, 75, 139-141.	5.2	4
65	The importance of quantifying genetic heterogeneity in ADPKD. Kidney International, 2014, 85, 236-237.	5.2	1
66	Does dopamine connect the dots in ADPKD?. Kidney International, 2015, 87, 279-280.	5.2	1
67	Response to: Heterogeneous Treatment Response by Race Cannot Be Claimed in the Absence of Evidence. American Journal of Hypertension, 2020, 33, e2-e2.	2.0	0
68	Cosmc Is Silenced in Human Tn4 B Cells through Hypermethylation of the Gene Promoter. FASEB Journal, 2012, 26, 928.7.	0.5	0
69	Human Cosmc and Tâ€synthase Genes Are Transcriptionally Regulated by SP1/SP3 Transcription Factors. FASEB Journal, 2012, 26, 931.13.	0.5	0